Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study will be a multicenter, randomized, vehicle controlled, parallel, group, double
blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to
one of four treatment groups: 1.5% CD07223 Topical Gel applied BID; 1.5% CD07223 Topical Gel
applied TID; Vehicle Topical Gel applied BID;Vehicle Topical Gel applied TID. All treatments
will be administered for 7 days. Disease activity for the Target Lesion will be evaluated
using the Skin Infection Rating Scale (SIRS) Score.